AGTC Genomics

08/10/2026

𝗛𝗼𝘄 𝗶𝘀 𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗻𝘂𝘁𝗿𝗶𝘁𝗶𝗼𝗻?

At the recent Entrepreneurial Leadership Forum: “Scaling Innovation for a One Health Future,” Samantha Wong, Chief Dietitian at AGTC Genomics, shared how nutrigenomics, nutriepigenomics and polygenic risk scores (PRS) are beginning to transform modern dietetics.

The same diet does not work equally well for everyone.

Our genes can influence how we respond to nutrients, fats, glucose, caffeine and other dietary factors, while lifestyle and diet can also influence gene regulation through epigenetic mechanisms.

With advances such as PRS, dietitians may be able to better understand an individual’s inherited susceptibility to conditions such as obesity, diabetes, dyslipidaemia and cardiovascular disease — allowing earlier and more targeted nutritional intervention.

The future of personalized nutrition may increasingly combine:

Genomics + PRS + biomarkers + microbiome + lifestyle + dietary behaviour

The goal is not a rigid “DNA diet”, but more personalized, preventive and evidence-informed nutrition.

At AGTC Genomics, we believe this represents an important step towards helping individuals better understand their health risks and make more informed dietary and lifestyle choices.

https://www.agtcgenomics.com/post/agtc-genomics-chief-dietitian-samantha-wong-highlights-the-future-of-personalized-nutrition

AGTC Genomics Chief Dietitian Samantha Wong Highlights the Future of Personalized Nutrition

06/10/2026

𝗖𝗮𝗻 𝘄𝗲 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲 𝗶𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗳𝗶𝗿𝘀𝘁 𝗴𝘂𝗲𝘀𝘀𝗶𝗻𝗴 𝘄𝗵𝗶𝗰𝗵 𝗽𝗮𝘁𝗵𝗼𝗴𝗲𝗻 𝘁𝗼 𝘁𝗲𝘀𝘁 𝗳𝗼𝗿?

At the recent Malaysia Microbiome Meeting 2026, AGTC Genomics presented its latest findings on Clinical Metagenomics — an NGS-based approach for broad, unbiased pathogen detection.

The study showed high concordance with conventional methods such as bacterial culture and PCR, while offering an important advantage: the ability to screen broadly for bacteria, viruses, fungi and parasites in a single test.

Instead of asking: “What pathogen should I test for?”

Clinical Metagenomics helps move towards: “What is actually causing the infection?”

AGTC Genomics’ current workflow covers approximately 700 clinically relevant pathogens, with a turnaround time of less than 24 hours, making it especially useful for difficult cases such as culture-negative infections, critically ill patients, atypical infections and cases where prior antibiotics may have reduced culture yield.

Importantly, the goal is not simply to detect more organisms, but to identify the most clinically relevant pathogen by combining sequencing results with microbial abundance, specimen type, symptoms and other clinical findings.

To further advance this work, AGTC Genomics, IMU University and UMMC have recently secured a joint research fund from MOSTI to support implementation across hospitals and to develop a local infectious disease genomic database and antimicrobial resistance reference database for Malaysia.

This is an important step towards more rapid, evidence-based and precision-driven infectious disease diagnostics.

One sample. Broad detection. Rapid interpretation. Actionable treatment.

https://www.agtcgenomics.com/post/agtc-genomics-presents-latest-clinical-metagenomics-findings-at-malaysia-microbiome-meeting-2026

NGS-based approach demonstrates high concordance with conventional microbiology while enabling broad, unbiased detection of bacterial, viral, fungal and parasitic pathogens in under 24 hoursKUALA LUMPUR, 3 October 2026 — AGTC Genomics presented its latest findings on Clinical Metagenomics for infe...

29/09/2026

🧬 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀. 𝗖𝗹𝗲𝗮𝗿𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀.

OncoDx™ brings comprehensive cancer genomic profiling into a single test — detecting multiple classes of genomic alterations and key signatures that may influence treatment decisions.

With results in 7–14 working days, clinicians receive clear, actionable genomic information to support more personalized cancer care.

Actionable results. Clear reports. Better outcomes.

25/09/2026

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗔𝗰𝗿𝗼𝘀𝘀 𝘁𝗵𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗮𝗿𝗲 𝗖𝗼𝗻𝘁𝗶𝗻𝘂𝘂𝗺

AGTC Genomics Chief Scientist, Dr Tan Boon Shing, recently delivered a CME talk at Thomson Hospital, highlighting advances in early cancer detection, comprehensive genomic profiling and liquid biopsy technology.

AGTC Genomics supports the entire precision oncology journey—from hereditary cancer risk assessment and multi-cancer early detection to identifying actionable mutations for targeted therapy and immunotherapy through tissue-based CGP and liquid biopsy, followed by minimal residual disease monitoring after treatment.

Through continuous research, innovation and clinical collaboration, AGTC Genomics is committed to making precision oncology more accessible and impactful for patients in Malaysia and across the region.

AGTC Genomics Highlights Advances in Precision Oncology at Thomson Hospital CME

25/09/2026

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗶𝗻 𝗦𝗮𝗯𝗮𝗵 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀

AGTC Genomics was pleased to deliver a Continuing Medical Education (CME) talk at Hospital Wanita dan Kanak-Kanak Sabah (Likas) on “Integrating Genomic Sequencing into Cancer Patient Management.”

Presented by ChM Ts Dr Tan Boon Shing, Chief Technology and Data Officer of AGTC Genomics, the session highlighted how comprehensive genomic profiling, hereditary cancer testing, liquid biopsy and molecular disease monitoring are increasingly supporting more informed and personalized cancer care.

By integrating genomic insights with clinical and pathological findings, clinicians can better understand the molecular profile of cancer, identify potentially actionable biomarkers, guide treatment strategies and monitor disease more precisely.

AGTC Genomics remains committed to advancing precision oncology education and genomic medicine across Malaysia, while supporting clinicians throughout the cancer care continuum — from cancer risk assessment and early detection to treatment selection and disease monitoring.

AGTC Genomics Advances Precision Oncology Education with CME Talk at Hospital Wanita dan Kanak-Kanak Sabah

25/09/2026

🧬 𝗙𝗿𝗼𝗺 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗙𝗶𝗻𝗱𝗶𝗻𝗴𝘀 𝘁𝗼 𝗕𝗲𝘁𝘁𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀

At the National Cancer Congress Malaysia 2026, Prof Dr Chee-Onn Leong, Founder and CEO of AGTC Genomics, shared how genomic profiling can help clinicians identify treatment-relevant changes in lung, breast and colorectal cancers.

The session was chaired by Prof Dr Ho Gwo Fuang, a senior consultant clinical oncologist with MRCP and FRCR qualifications. Dr David Lee Dai Wee and Prof Dr Chin Kin Fah also presented, followed by a fruitful discussion with delegates.

Comprehensive genomic profiling can give clinicians a broader picture of a tumour—helping them consider targeted treatments, clinical trials and the most appropriate next steps for each patient.

At AGTC Genomics, we are committed to turning genomics research into accessible tools for cancer care.

The role of precision oncology in clinical practice took centre stage at the recently concluded National Cancer Congress Malaysia (NCCM) 2026, organised by the National Cancer Society of Malaysia (NCSM) and Sunway University.Presenting Genomic Landscape of Common Cancers in Malaysia, Professor Dr Ch...

24/09/2026

𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗥𝗲𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝘀 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 𝗮𝘁 𝘁𝗵𝗲 𝟭𝟰𝘁𝗵 𝗖𝗵𝗶𝗻𝗮–𝗔𝗦𝗘𝗔𝗡 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗧𝗿𝗮𝗻𝘀𝗳𝗲𝗿 & 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗙𝗼𝗿𝘂𝗺

AGTC Genomics was proud to represent Malaysia at the 14th Forum on China–ASEAN Technology Transfer and Collaborative Innovation in Nanning, China — an important G2G platform connecting China and ASEAN in technology transfer, research collaboration and innovation, organized by the China-Asean Technology Transfer Center (CATTC)

The Malaysian delegation included representatives from MOSTI, MRANTI, Universiti Malaya (UM), AGTC Genomics, and other key organisations, alongside prominent healthcare and MedTech leaders from across Southeast Asia.

Representing AGTC Genomics, our Chief Technology Officer, Dr Tan Boon Shing, shared the latest trends and developments in precision medicine in Malaysia, highlighting the growing role of genomics, molecular diagnostics and data-driven healthcare in transforming clinical practice.

Our participation reflects AGTC Genomics’ continued commitment to strengthening Malaysia’s position as a regional hub for precision diagnostics and genomic medicine, while building stronger international collaborations across China and ASEAN.

From Malaysia to the region, we remain committed to advancing precision diagnostics and translating genomic innovation into better healthcare outcomes.



https://www.agtcgenomics.com/post/agtc-genomics-represents-malaysia-at-the-14th-china-asean-technology-transfer-and-collaborative-inno

Chang Lih Kang

Malaysia’s precision diagnostics capabilities showcased on an important government-to-government platform connecting China and ASEAN in technology, healthcare and innovationNANNING, CHINA, September 2026 — AGTC Genomics was proud to represent Malaysia at the 14th Forum on China–ASEAN Technolog...

24/09/2026

𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 𝗯𝘆 𝗗𝗮𝘆, 𝗣𝗵𝗗 𝗖𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲 𝗧𝗵𝗿𝗼𝘂𝗴𝗵𝗼𝘂𝘁 — 𝗪𝗲𝗹𝗰𝗼𝗺𝗶𝗻𝗴 𝗠𝘀. 𝗡𝗴 𝗭𝗵𝗶 𝗪𝗶𝗻

We're delighted to welcome Ms. Ng Zhi Win to AGTC Genomics as our new Scientist.

Zhi Win holds a BSc in Biomedical Science (First-Class Honours) from the University of Malaya, with experience spanning biotechnology, clinical research and molecular laboratory work. She is currently pursuing her PhD at IMU alongside her role with us.

At AGTC Genomics, she applies her expertise in molecular techniques, genomics and biotechnology to support our genomic research and diagnostic services — bringing an active researcher's perspective to the work we deliver every day.

🧬 Molecular Techniques | 🔬 Genomics | 🧫 Biotech Research | 📋 Clinical & Lab Experience

We're excited to have you on board, Zhi Win, and look forward to the impact we'll create together. Welcome aboard! 👏

Innovating Genomics, Improving Lives.

23/09/2026

𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻𝘁𝗼 𝗖𝗹𝗶𝗲𝗻𝘁 𝗩𝗮𝗹𝘂𝗲 — 𝗪𝗲𝗹𝗰𝗼𝗺𝗶𝗻𝗴 𝗢𝘂𝗿 𝗡𝗲𝘄 𝗣𝗿𝗼𝗱𝘂𝗰𝘁 & 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁

We're pleased to welcome Mr. Lim Xue Yuan to AGTC Genomics as our new Product & Applications Specialist.

Xue Yuan holds a BSc in Genetics and Bioinformatics from Monash University, and supports client engagement, solution development and the adoption of genomics technologies among research institutions and industry partners.

Working closely with our scientific and commercial teams, he translates complex genomic capabilities into practical, value-driven solutions that address real client needs — strengthening partner confidence and driving solution uptake. It's a role that pairs scientific depth with commercial focus, contributing to our business development and scalable B2B growth.

🤝 Client Engagement | 💡 Solution Development | 🧬 Genomic Technologies | 📈 B2B Growth

We're excited to have you on board, Xue Yuan, and look forward to the impact we'll create together. Welcome aboard! 👏

Innovating Genomics, Improving Lives.

22/09/2026

🔬 𝗠𝗼𝗿𝗲 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀. 𝗠𝗼𝗿𝗲 𝗼𝗽𝘁𝗶𝗼𝗻𝘀. 𝗕𝗲𝘁𝘁𝗲𝗿 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀.

Cancer treatment is increasingly driven by the molecular characteristics of each tumour.

OncoDx™ Comprehensive Genomic Profiling analyzes up to 523 genes and key genomic signatures, helping clinicians identify actionable alterations and potential treatment options from a single comprehensive test.

Advancing precision oncology, one patient at a time.